Resistance to chemotherapy and molecularly targeted therapies: Rationale for combination therapy in malignant melanoma

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a "vertical" or "horizontal" combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.

Original languageEnglish (US)
Pages (from-to)553-563
Number of pages11
JournalCurrent Molecular Medicine
Volume11
Issue number7
DOIs
StatePublished - Jan 1 2011

Fingerprint

Chemotherapy
Tumors
Melanoma
Drug Therapy
Survival
Defects
Neoplasms
Cell Survival
Intercellular Signaling Peptides and Proteins
Therapeutics
Quality of Life
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Drug resistance
  • Melanoma
  • Targeted therapy

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Cite this

@article{53004e3f533544d6924b9efb1070c45a,
title = "Resistance to chemotherapy and molecularly targeted therapies: Rationale for combination therapy in malignant melanoma",
abstract = "Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a {"}vertical{"} or {"}horizontal{"} combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.",
keywords = "Chemotherapy, Drug resistance, Melanoma, Targeted therapy",
author = "S. Wu and Singh, {Rakesh K}",
year = "2011",
month = "1",
day = "1",
doi = "10.2174/156652411800615153",
language = "English (US)",
volume = "11",
pages = "553--563",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Resistance to chemotherapy and molecularly targeted therapies

T2 - Rationale for combination therapy in malignant melanoma

AU - Wu, S.

AU - Singh, Rakesh K

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a "vertical" or "horizontal" combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.

AB - Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a "vertical" or "horizontal" combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.

KW - Chemotherapy

KW - Drug resistance

KW - Melanoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=80053977936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053977936&partnerID=8YFLogxK

U2 - 10.2174/156652411800615153

DO - 10.2174/156652411800615153

M3 - Article

C2 - 21707515

AN - SCOPUS:80053977936

VL - 11

SP - 553

EP - 563

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 7

ER -